Heng Xie, MD, PhD, MPH

Medical Officer/Program Director, Clinical Grants and Contracts Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD, USA

Dr. Xie is a Medical Officer and Program Director in the Clinical Grants and Contracts Branch; joining CTEP in 2001. As Program Director, he is responsible for the oversight of a portfolio of grants and cooperative agreements supporting clinical research studies on solid tumors. These studies involve clinical cancer treatment trials, related correlative and pharmacogenomic studies, and statistical methodology development. As Medical Officer, he plays an integral role, along with the Investigational Drug Branch and Clinical Investigations Branch, in initiation and review of CTEP supported Phase I, II, and III cancer treatment trials.

Dr. Xie received his MD degree and surgical residency training in China, holds U.S. Educational Commission for Foreign Medical Graduates certification, and a MPH degree from Johns Hopkins University. Dr. Xie earned a PhD in Molecular and Cellular Pathology from the University of Alabama at Birmingham. His research focused on cell signal transduction and mechanisms of tumor invasion and metastasis. As a postdoctoral fellow at the NCI, Dr. Xie obtained his interdisciplinary training in Epidemiology, Biostatistics, and Clinical Trials. He has published numerous peer-reviewed articles in basic, translational, epidemiological, and drug developmental research. Currently, Dr. Xie is actively involved in trans-NCI/NIH activities and committees while leading a collaborative effort to publish NCI mission-oriented program announcements.